NCT06973343View on ClinicalTrials.gov

Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

December 31, 2027

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Group A

Sintilimab 200mg Bevacizumab 7.5mg/kg Oxaliplatin 130mg/m2 Capecitabine 1250mg/m2

DRUG

Group B

Sintilimab 200mg Bevacizumab 7.5mg/kg Irinotecan 150mg/m2 Capecitabine 1250mg/m2

Trial Locations (1)

230000

Anhui provincial cancer hospital, Hefei

All Listed Sponsors
lead

Anhui Provincial Cancer Hospital

OTHER